Zhengye Biotechnology Holding Limited (ZYBT)
ZYBT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1975641/000121390026048584/0001213900-26-048584-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZYBT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | China |
| IPO year | 2025 |
| SEC CIK | 0001975641 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | China |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $16.6M |
| Net income | -$10.0M |
| Operating income | -$10.1M |
| Net margin | -60.0% |
| Operating margin | -60.6% |
| Revenue growth | -34.8% |
| Cash | $7.2M |
| Total assets | $62.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-28 |
| Cash and burn | $7.2M cash; operating cash flow $478K a quarter. | Report 2025-12-31 |
| Shares outstanding | 47,391,376 (2025-12-31); 45,666,376 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WWC, P.C., San Mateo, California, United States | PCAOB Form AP 2026-05-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $16.6M | -$10.0M | $1.9M | $7.2M | $10.7M | $16.6M | 20-F 2026-04-28 |
| FY 2024 2024-12-31 | $25.5M | $1.6M | $5.6M | $2.5M | $11.8M | $25.5M | 20-F 2025-07-03 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2025-01-07 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-04-28 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 62 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | 0.0% |
| 1 month | +1.4% |
| 3 months | -2.0% |
| Year to date | +30.4% |
| 1 year | -30.2% |
| From 52-week high | -81.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TENX | Tenax Therapeutics Inc. | $1.48 | -8.64% | $67.4M |
| GOSS | Gossamer Bio Inc. | $10.98 | +0.09% | $67.2M |
| MNOV | Medicinova Inc | $1.34 | -3.94% | $68.7M |
| CRBP | Corbus Pharmaceuticals Holdings Inc. | $3.38 | -0.44% | $69.5M |
| COYA | Coya Therapeutics Inc. | $3.00 | -4.15% | $70.4M |
| VTVT | vTv Therapeutics Inc. | $17.69 | -10.16% | $71.0M |
| TLSA | Tiziana Life Sciences Ltd. Common Shares | $0.5762 | +1.11% | $73.3M |
| ACRV | Acrivon Therapeutics Inc. | $1.46 | +0.69% | $62.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier